Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
  • A01K67/027—New or modified breeds of vertebrates
  • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/61—Growth hormone [GH], i.e. somatotropin
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/82—Translation products from oncogenes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2217/00—Genetically modified animals
  • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2227/00—Animals characterised by species
  • A01K2227/10—Mammal
  • A01K2227/105—Murine
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2267/00—Animals characterised by purpose
  • A01K2267/03—Animal model, e.g. for test or diseases
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2830/00—Vector systems having a special element relevant for transcription
  • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Definitions

• cyto- plasmic alpha granules appear, which contain hemostatic system mediators such as platelet factor 4 (PF4) and growth factors such as platelet derived growth factor (Odell, T.T. Jr. and Jackson, C.W. (1968) Blood 32, 102-110; Paulus, J.-M. (1970) Blood 3_5, 298-311; Ebbe, S. and Stohlman, F.Jr. (1965) Blood 2_6, 20-35; Oyo, R. , Nakeff, A., Huang, S.S., Ginsberg, M. , and Deuel, T.F. (1983) J. Cell Biol.
• PF4 platelet factor 4
• platelet derived growth factor Odell, T.T. Jr. and Jackson, C.W. (1968) Blood 32, 102-110; Paulus, J.-M. (1970) Blood 3_5, 298-311; Ebbe, S. and Stohlman, F.Jr. (1965) Blood 2
• the complex interactions between specific receptors, signalling pathways, and cytoplasmic granules allow platelets to bind to adhesive proteins exposed on damaged blood vessels, complex with plasma components that accelerate blood coagulation, release alpha granule constitutents which modulate blood clotting as well as stimulate wound healing, and take part in plasma protein mediated platelet-platelet aggregate formation which seals damaged areas of the vascular tree (Hawiger, J. , Steer, M. , and Salzman, E.
• the present invention relates to a method of selective targeting of a gene product through the use of a megakaryocyte promoter; constructs useful in the method of selective targeting; transgenic mammals in which a megakaryocyte promoter selectively targets a gene product to bone marrow megakaryocytes, circulating platelets and the adrenal gland; and a method of treating or preventing a condition or disease in which the level of a critical component of megakaryocytes or platelets is altered by selectively augmenting or suppressing the level of the component. It further relates to a method of assessing the function of a critical component of megakaryocytes or platelets by altering its level and determining the effects of the modification.
• the present invention provides a means of targeting a selected substance, such as a diagnostic, therapeutic or preventive substance, to any area of the body at which a nucleic acid sequence encoding the selected substance is delivered and expressed under the control of a mega ⁇ karyocyte promoter.
• a selected substance such as a diagnostic, therapeutic or preventive substance
• platelets, bone arrow megakaryocytes and the adrenal gland have been shown to selectively contain the product of a gene coupled to the platelet factor 4 promoter and, thus, each can be targeted as a site for expression of a nucleic acid sequence encoding a selected substance.
• the present invention is useful, for example, as a means of targeting delivery of a selected substance, such as a growth factor or tissue plasminogen activator (tpa) , by means of platelets containing a nucleic acid sequence encoding the selected substance, to an area to which platelets migrate in vivo (e.g., an affected area such as a wound or site of a myocardial infarct) .
• a selected substance such as a growth factor or tissue plasminogen activator (tpa)
• tpa tissue plasminogen activator
• the present invention provides a method of targeting to the adrenal gland a selected substance, such as a glucocorticoid or other drug bene ⁇ ficial to the adrenal gland.
• it is possible to use the present method in treating conditions in which megakaryocyte function is altered, such as in mega ⁇ karyocyte leukemia.
• Figure 1 is a 1181 bp nucleotide sequence of the rat PF4 gene.
• the transcription start site is indicated in a box; the GATAAA sequence is underlined; and the sequence linked to the HGH gene in PPF4GH is indicated by an arrow.
• Figure 2A is a schematic representation of the PF41acZ construct, which contains 1.1 kb of the 5' upstream region of the rat PF4 promoter linked to the 3.34 kb of the prokaryotic ⁇ -galactosidase (lacZ) gene without its regulatory region.
• Figure 2B is a photograph of a Southern blot of mouse DNAs prepared from F2 offspring of founder 10. Lanes 1,2: ho ozygotes; lanes 3,5: nontransgenic mice; lanes 4, 6, 7 and 8: heterozygotes. ⁇ Hindlll markers are indicated by arrows.
• Figure 3 shows expression of the PF4lacZ construct in hematopoietic cells.
• In situ staining for prokaryotic ⁇ -galactosidase was carried out on a peripheral blood smear of a transgenic mouse (A) ; purified platelet fractions from a transgenic mouse (B) or a normal litter mate (not shown) ; bone marrow from a transgenic mouse (C) or a normal litter mate (D) ; splenic tissue section from a transgenic mouse (E) ; and thy ic tissue section from a transgenic mouse (not shown).
• Figure 4 shows expression of the PF41acZ construct in adrenal gland from a transgenic mouse. In situ staining for prokaryotic 0-galactosidase was carried out on tissue sections of the adrenal gland from a transgenic mouse (A) and a normal litter mate (not shown) . Magnifi ⁇ cation: x40.
• a tissue specific promoter can be used to target delivery to and expression of a selected substance or gene product to a tissue or tissues.
• a megakaryocyte promoter coupled to a nucleic acid sequence ' encoding a selected substance is useful for selective expression of the encoded substance in plate ⁇ lets, bone marrow megakaryocytes and the adrenal gland.
• the 5' upstream region of the platelet factor four (PF4) promoter has been coupled to a gene encoding a selected product and expressed in a transgenic mammal.
• megakaryocytes were the only circulating blood cells and megakaryocytes were the only hemato- poietic precursor cells in which the selected product occurred.
• the selected product was also evident to a lesser extent in the adrenal gland, in which its dis ⁇ tribution corresponded to the location of mineralo- corticoid secreting cells.
• the megakaryocyte promoter described is the PF4 promoter, which has a high power of expression in cells of this type.
• it offers the advantage of a high level of expression of a protein in platelets.
• another megakaryocyte promoter such as the lib gene promoter, can be used to target genes of interest to megakaryocytes and circulating platelets.
• the 5' up ⁇ stream region of the PF4 promoter used contains most, if not all, of the tissue specific region.
• Figure 1 shows a 1181 bp nucleotide sequence of the rat PF4 gene.
• Transient expression experiments which are described in greater detail in Example 1 revealed a complex interplay between a core promoter domain from -97 to the trans- criptional start site, and an enhancer silencer domain from -448 to -112.
• the core promoter contains a GATA site at -31 to -28 whose mutation to TATA or AATA decreases tissue specifi ⁇ city and moderately affects expression in megakaryocytes as well as a postive-acting subdomain from -97 to -83 whose removal decreases overall transcription without affecting tissue specificity.
• the enhancer/silencer domain possesses three positive-acting subdomains from -380 to -362, -270 to -257 and -237 to -120 as well as a negative-acting subdomain at -184 to -151 which is able to reduce overall transcription but has no effect on tissue specificity.
• the subdomain -380 to -362 is most critical in restricting gene expression driven either by the PF4 promoter or by a heterologous promoter to the megakaryocytic lineage.
• the subdomains -270 to -257 and -137 to -120 function together with subdomain -380 to -362 to somewhat increase tissue specificity.
• the PF4 promoter region can be linked to a nucleic acid sequence(s) or gene(s) of interest (i.e., encoding a selected product(s) and used to produce transgenic mammals or introduced into an individual (prenatally or postnatally) .
• a PF4 promoter region-nucleic acid sequence construct can be produced and introduced, as described herein, at an embryonic stage, such as into the pronuclei of fertilized eggs, which are reimplanted into a female and maintained under appropriate conditions for development.
• the resulting offspring contain the construct and the encoded product is targeted specific ⁇ ally to platelets, bone marrow megakaryocytes and the adrenal gland.
• the PF4 promoter region can be linked to a nucleic acid sequence(s) or gene(s) to form a PF4 promoter region-nucleic acid sequence con ⁇ struct which can be introduced into bone marrow of an individual (e.g., prior to bone marrow transplantation) for selective targeting of the encoded product to plate ⁇ lets, megakaryocytes and the adrenal gland.
• PF41acZ a construct, referred to as PF41acZ, which includes a megakaryocyte promoter region and a gene encoding ⁇ -galactosidase and its use in producing two lines of transgenic mice which express the construct
• characterization of the trans ⁇ genic mice, particularly as to location of expression of the construct and 3) application of the present finding to selectively target gene products.
• the PF4lacZ construct and its use in generating transgenic mice are described in detail in Example 1.
• the PF41acZ construct includes l.lkb of the 5' upstream region of the rat PF4 promoter linked to the 3.34 kb of the prokaryotic ⁇ - galactosidase (lacZ) gene without its regulatory region.
• lacZ prokaryotic ⁇ - galactosidase
• a full length rat PF4 cDNA has been isolated and sequenced by Doi and co-workers. Mol. and Cell. Biology, 7:898-904(1987). The teachings of this reference are incorported herein by reference.
• the l.lkb genomic PF4 fragment includes 1104 bases of the 5' upstream sequence and the cap site to +20.
• PF4 This segment of the PF4 gene was selected because transient expression assays utilizing primary bone marrow cells suggested that the tissue specific regulatory elements are located within this domain. Ravid, K. et al. , FASEB J. Abstract 1392 (1990).
• the PF4 fragment was inserted into a PUC19-based plasmid (pSDKlacZpA) which contains the 3.34 kb pro ⁇ karyotic ⁇ -galactosidase gene without its upstream regulatory region, flanked by a unique Hindlll site at the 5' end and a unique BamHI site at the 3' end.
• Plasmid PF41acZ was deposited (September 28, 1990), under the terms of the Budapest Treaty, at the American Type Culture Collection (Rockville, MD) under accession number 40903.
• transgenic mice Production of the transgenic mice is described in Example 2, as is assessment of tissue distribution of the product ( ⁇ -galactosidase) .
• Two lines (line 10 and line 12) of transgenic mice which express the construct were generated, as explained in Example 2.
• Transgenic mice from both lines were assessed for expression of the PF41acZ construct or transgene in peripheral blood cells, bone marrow progenitor cells, splenic cells, thymic cells, and cells from other organs (adrenal gland, brain, heart, intestine, kidney, liver, lung and skeletal muscle) . Normal litter mates served as controls.
• a selected nucleic acid sequence (a gene or gene fragment) is linked to a megakaryocyte promoter in such a manner that expression of the nucleic acid sequence is under the control of the megakaryocyte promoter.
• the resulting megakaryocyte promoter-nucleic acid sequence construct is introduced into a mammal under conditions appropriate for expression of the product encoded by the nucleic acid sequence.
• the construct can be used to produce transgenic animals or can be introduced into an individual (e.g., into somatic cells).
• the construct can be used to overexpress (cause increased expression of) a gene or nucleic acid sequence, as well as to underexpress (cause reduced expression of) a gene or nucleic acid sequence.
• a gene encoding, for example, a growth factor can be overexpressed.
• an active form of a specific gene product can be underexpressed in order to assess its effect on a wound healing model or on megakaryocyte development. This can be done by overexpressing a mutated form of a protein subunit, resulting in a significant decrease in the level of the active protein (i.e., an inactive dimer) .
• an antisense gene can be overexpressed, resulting in inactivation of a platelet or megakaryocyte gene.
• the megakaryocyte promoter in the construct can be, for example, the platelet factor 4 (PF4) promoter, the li gene promoter region or other megakaryocyte promoter. Based on what is disclosed herein with regard to the regulatory elements of the PF4 promoter, other mega ⁇ karyocyte promoters can be isolated and used to selec ⁇ tively target gene products as disclosed herein.
• PF4 platelet factor 4
• other mega ⁇ karyocyte promoters can be isolated and used to selec ⁇ tively target gene products as disclosed herein.
• the term megakaryocyte promoter as used herein means all or a portion of a megakaryocyte promoter; a promoter portion is one of appropriate size and sequence to have the desired function (ability to cause tissue specific expression of a nucleic acid sequence) .
• the ega- karyocyte promoter component of the construct can be obtained (isolated) from a naturally-occurring source or can be produced using any of a variety of techniques, such as genetic engineering or cloning methods, PCR amplification or synthetic techniques.
• the promoter described herein is of murine origin, it can be from another source (or have the sequence of a mega ⁇ karyocyte promoter of other than murine origin) .
• it can be of human origin and preferably will be in those applications carried out in humans.
• the sequence of the megakaryocyte promoter component of the construct need not be precisely the same as that of a megakaryocyte promoter, but must only be sufficiently similar that it have the desired function for which a megakaryocyte promoter is used (i.e., tissue selective expression of a selected gene or nucleic acid sequence) .
• the gene(s) or selected nucleic acid sequence(s) in the construct encode one or more products whose expression in platelets and megakaryocytes is desired.
• the gene(s) or selected nucleic acid sequence(s) can also be targeted to the adrenal gland.
• the gene or nucleic acid sequence can be obtained (isolated) from a naturally-occurring source or can be produced using any of a variety of techniques, such as genetic engineering or cloning methods, PCR amplification or synthetic techniques. For example, a gene encoding tissue plasminogen activator
• tpa can be incorporated into a construct of the present invention and used to treat or prevent occlusions, such as occur in myocardial infarcts.
• a gene encoding a growth factor can be incorporated into a megakaryocyte promoter-nucleic acid sequence construct and introduced into an individual to enhance wound healing or vascular proliferation.
• a key advantage to expression of a selected product such as tpa or a growth factor in platelets is that platelets migrate to the affected areas (e.g., wound, occlusion) and, as a result, will concentrate delivery of the encoded product at the site or sites at which it is needed, rather than intro ⁇ ducing the product in a more systemic manner.
• a mega ⁇ karyocyte promoter-growth factor construct can also be used to produce an immortalized cell line of mega ⁇ karyocytes, depending on the growth factor and the sensitivity of the megakaryocyte to the factor being overexpressed.
• a particular advantage to the present invention is that it provides a means of targeting a selected product to platelets, which contain coagulation factors which accelerate blood clotting, adhesive pro ⁇ teins which facilitate the interactions of platelets and other blood cells and growth factors which stimulate the process of wound healing.
• Another advantage to use of a construct of the present invention is that it provides a means by which continuous production of the encoded substance is possible. That is, because the gene en ⁇ coding the selected product is present in a cell, it will continue to be expressed for the life of the cell.
• a further advantage to use of a construct of the present invention is that expression of the particular product can be controlled (i.e., can be turned on or off) by manipulating the regulatory elements.
• expression can be turned off by mutating the GATA site and/or deleting positive regulatory domains as as P.
• the construct of the present invention can be used to produce transgenic animals, in which it is expressed on an ongoing basis and transmitted to offspring.
• a construct can be introduced into an individual in need of therapy or preventive treatment.
• a construct can be introduced into bone marrow megakaryocytes, using known techniques, such as a retroviral vector.
• platelets produced will contain the construct, express the encoded product and serve as a production and delivery system for the product.
• Transgenic animals in which the megakaryocyte promoter-nucleic acid sequence construct results in production of a reporter gene can be used in develop ⁇ mental biology experiments.
• an oncogene can be introduced into an animal model expressing a reporter gene, such as ⁇ -galactosidase, driven by the PF4 promoter to analyze the effect of the insertional locus of these oncogenes on the loss of differentiation and tissue specific expression.
• the transgenic mouse produced as described herein, in which the PF4 promoter drives a marker gene can be used to assay the effect of agents on megakaryocyte differentiation and platelet formation, by means of detecting -galactosidase activity.
• a marker gene e.g., the prokaryotic -galactosidase gene
• an iji vitro assay can be carried out to assess the effects of different agents, such as thrombopoietin (McDonald, T. P. , "Thrombopoietin: Its Biology, Purification and Characterization", Exptl. Hematology, 16 (1988) , on megakaryocytes in cultured bone marrow.
• ⁇ -galactosidase serves as a selectable marker for megakaryocytes.
• an in vivo model can be used for assessing platelet pro ⁇ duction and megakaryocyte ploidy by assaying for ⁇ - galactosidase in bone marrow of transgenic mice subjected to manipulations designed to alter or influence platelet production or megakaryocyte ploidy (e.g., treatment with thrombopoietin) .
• Transgenic animals can also be produced using a construct in which an oncogene is under the control of the megakaryocyte promoter.
• a megakaryocyte promoter-oncogene construct can be introduced, as des ⁇ cribed herein, to produce transgenic mice from which immortalized adrenal cortex cells can be obtained.
• the PF4 promoter can be linked to the temperature sensitive mutated form of the large T antigen and introduced into mice, producing transgenic mice.
• a cell line of immortalized megakaryocytes can be produced by obtaining bone marrow cells into which the oncogene- containing construct has been introduced and growing them in vitro at a permissive temperature. Such immortalized megakaryocyte cell lines can be used, for example, in in vitro study of megakaryocyte differentiation.
• Plasmids pOGH and pSVTKGH were a generous gift from R.F. Selden, Boston, MA.
• pPF4GH was constructed by digesting a plasmid containing the rat PF4 gene (Doi, T. et al. , Mol. Cell. Biol. 7:898-904 (1987)) with EcoRI and Bamll, ligating the resultant fragment spanning the 5' upstream region from -1104 to +20 with the synthetic linkers.
• control plasmid for the HIRT assay was generated by linearizing pOGH with Hindlll, treating the linearized plasmid with alkaline phosphatase, and then ligating a 6.5 Kb Hindlll fragment of the human thrombomodulin (TM) gene into this site.
• the 5' deletions of the pPF4GH were carried out with the Erase-a-Base system.
• the plasmid was digested with Ndel and 5' protruding ends were filled with Klenow fragment as well as alpha-thiodeoxynucleotide triphos- phates.
• the resultant fragment was then cut with Stul at a site -170 bp downstream of the 5' ' end of the sequence, and digested for varying times with exonuclease III.
• the nucleotide sequences of deleted mutants were determined by the dideoxy sequencing method.
• the 5" deletant from -273 was specifically constructed by removing the Ndel to Accl (-255) fragment of pPF4GHd (see below) and then inserting synthetic DNA to replace -272 through -255 as well as restore the Ndel site.
• the internal deletions, replacements, and mutations of pPF4GH were mainly carried out with PCR generated fragments utilizing as template M13mpl9 viral DNA con- taining the Hindlll (PF4) to SacI (GH) fragment (M13-
• PCR was conducted in 50 uM KC1 and 1.5 to 3 mM MgCl 2 in 10 mM Tris-HCl, pH 8.3, with 200 ⁇ M dNTPs and l ⁇ M primers. The reactions were performed for 20-25 cycles of 1 min at 94°, 1 min at 42°-55°, and 2 min at 72 ⁇ C. The integrity of product ends was insured by incubating with 5 units of Klenow for 15-20 min at 24°. The structures of the fragments were confirmed by dideoxy sequencing.
• a Hindlll (-735) to Xbal (-20) fragment was subcloned into pBluescript [pBSrPF4(H-X) ] since the Bglll site at -122 and the BamHI site at -222 are unique.
• the modified fragments were eventually exported to pPF4GHd.
• pPF4GHd was obtained by removing adapter and polylinker sequences between the rat promoter and the GH gene of pPF4GH such that nucleotide +16 of the rat gene is linked to +2 of the GH gene which provided a unique Xbal site at -20.
• the pPF4GH sequence from -444 to -112 was deleted by digesting a bBluescript clone containing a Smal fragment of rPF4 (-844 to -59) with Sfa Nl (-449) , blunting with Klenow, and cutting with HindiI I (-736) .
• Hindlll to Sna Nl fragment was isolated and then ligated with pPF4GH from which the Hindlll (-735) to Seal (-112) fragment had been removed by partial Seal digestion.
• the pPF4GH GATA sequence from -31 to -28 was mutated to AATA or TATA by carrying out PCR with a sense primer spanning -265 to -249 and a degenerate antisense primer spanning -18 to -40 with A/T replacing G at -31 in conjunction with the template M13-PFGH.
• the product was self ligated, digested with Bglll and Xbal, and ligated with pBS rPF4 (H—X) from which the Bglll to Xbal rPF4 fragment had been excised. Recombinants were identified by- sequencing, and Hindlll to Xbal fragments carrying AATA and TATA sequences were exported back tp pPFGHd.
• the TATA mutation of the GATA sequence was also prepared within the pPFGH deletant at -97 by partially digesting the plasmid with Xbal (2 sites 49 bp apart) as well as BspEll and then removing the small fragments generated.
• the resultant cut plasmid was then ligated to the BspEll to Xbal fragment of the PF4 promoter carrying the TATA/AATA mutations.
• the BspEll to Xbal fragments containing the TATA/AATA mutations were also used to replace native fragments in pPF4GHducta.
• the pPF4GH sequence from -97 to -83 was deleted by performing inverse PCR on a self ligated 940 bp Accl fragment derived from pPF4GHd with a sense primer spanning -82 to -67 and antisense primer spanning -98 -115.
• the product of the expected size was self- ligated, giested with Bglll and Xbal and ligated into pBSrPF (H-X) from which the corresponding fragment had been excised.
• the Hindlll to Xbal fragment of a recombinant confirmed by sequencing was exported back to pPF4GHd.
• the pPF4GH sequence from -137 to -116 was deleted and an Aflll site created by carrying out PCR employing an antisense primer spanning -96 to -115 as well as -138 to -157 and a sense primer spanning -463 to -445 in conjunction with the M13-PF4GH template.
• the product was digested with BamHI (-222) and Seal (-112) , and the resultant fragment between these two sites was isolated.
• the PBSrPF4 (H-X) was digested completely with BamHI and partially with Seal (2 sites) , the product singly cut at the rPF4 Seal site was purified, and then ligated with the above PCR fragment.
• the Hindlll to Xbal fragment was then exported to PF4GHd.
• the pPF4GH sequence from -212 to -149 was deleted by partially digesting pPF4GHd with BamHI (-222) as well as Bglll (-122) , and then isolating the resultant product of the largest size.
• the excised segment was replaced with a synthetic oligonucleotide of 45 bp which resulted in the removal of nucleotides -212 to -149, their replace ⁇ ment with AGCTGGTAC, and the introduction of unique Nhel and Kpnl sites.
• the above construct was cut with Kpnl, treated with alkaline phosphatase and ligated with polynucleotide kinase treated duplex C(AT) _GGTAC.
• the pPF4GH sequence from -270 to -257 was deleted by carrying out PCR employing an antisense primer spanning -236 to -256 as well as -271 to -290 and a M13 reverse sequencing sense primer in conjunction with the M13-PF4 template.
• the resultant product was digested with Hindlll and Accl and ligated to pPFHGH pre-cut in the same sites (pPF4GHdc) .
• pPF4GHdc a second Accl in the second intron of HGH was removed.
• the pPF4GH sequence from -380 to -362 was deleted by carrying out PCR employing an anti ⁇ sense primer comprised of the last five nucleotides of a SnaBl recognition site and -381 to -395 and a sense primer spanning -361 to -345 in conjunction with the self ligated Bglll (-756) to BamHI (-222) fragment template derived from pPFGHd.
• the PCR products of the expected sizes were isolated, self ligated and digested with
• Hindlll and Accl The resultant products were ligated with vector prepared by removing the Hindlll to Accl fragment from pPFGHdca. Recombinants were identified by the appearance of a SnaBl site (pPF4GHdua) . The sequences from -137 to -116 and -270 to -257 were deleted by digesting the pBSrPF4 (H-X) containing the -137 to -116 deletion with Hindlll and BamHI. The Hindlll to BamHI fragment was replaced with the corresponding fragment from pPF4GHdc and the Hindlll to Xbal fragment from the resulting recombinants was exported back to pPF4GHd (pPF4GHdct) .
• the pPF4GH sequences from -270 to -257 and -380 to -362 were deleted as outlined for -380 to -362 except that the Bglll to BamHI template was derived from pPF4GHdc (pPF4GHduca) .
• the pPF4GH sequences from -137 to -116, -270 to -256, and -380 to -362 were deleted by removal of the Accl to Xbal fragment from pPF4GHduca and its replacement with the corresponding fragment from pPF4GHdt (pPF4GHducta) .
• the PF4 regulatory sequences above -112 were in- serted upstream of the heterologous TK promoter in order to test these segments for tissue-specific enhancer function.
• the pPF4GH was cut with Ndel (-1104) and Seal (-112), or SfaNl (-448) and Seal (-112) and pPF4GH -273 was cut with Ndel (-273) and Seal (-112) .
• the various resultant fragment were blunted with Klenow, individually inserted into the unique Ndel site of pTKGH (230 bp upstream of the TK promoter) which had been blunted as well as treated with alkaline phosphatase, and then selected for correct orientation.
• PF4 regulatory sequences above -112 but with internal deletions were also linked to the heterologous TK pro ⁇ moter.
• pPF4GHdua, pPF4GHdct, and pPF4GHducta were cut with SfaNl (-448) as well as Seal (-112) , and the resultant fragments were individually inserted into pTKGH as outlined above.
• the PF4 enhancer domain was also inserted 1.2 kB upstream of the TK promoter.
• the bone marrow cells were grown in 5% CO- at 37°C in Iscove's Modification of Dulbecco's Medium (IMDM) supplemented with 200 units/ml of penicillin, 200 ug/ml of streptomycin, 0.592 mg/ml of L-glutamine, 15% rat plasma-derived serum or 20% horse serum, 1 unit/ml of erythropoietin and 10 units/ml of GM-CSF.
• IMDM Dulbecco's Medium
• penicillin 200 ug/ml of streptomycin
• 0.592 mg/ml of L-glutamine 15% rat plasma-derived serum or 20% horse serum
• 1 unit/ml of erythropoietin and 10 units/ml of GM-CSF The culture conditions were chosen to promote maximal growth of myeloid cells, erythroid cells, and megakaryocytes (Kuter, D.J. et al.. , Blood 74:1952-1962 (19
• HEL cell line The human erythroleukemia cell line, HEL cell line, was grown as described previously (Papayannopoulou, Th. et al.. Blood 72:1029-1038 (1988)). Bovine skin fibroblasts were cultured in the presence of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and antibiotics. Tra ⁇ sfection and Transient Expression Assay Conditions: Electroporation was used for the trans- fection of bone marrow cells and HEL cell lines (passages 8-12) essentially as described by Narayanan et al. , Biochem. Biophys. Res. Commun. 141:1018-1024 (1986).
• DMEM Dulbecco's Modified Eagle Medium
• the levels of HGH secreted by bone marrow cells or HEL cells after 72 hr in culture increase linearly as a function of plasmid concentration used for transfection, with 60 ug producing maximal transient expression.
• the concentrations of HGH secreted by cells transfected with 57 ug of circular pPF4GH also increase linearly as a function of time until about 96 hr in culture.
• a standard transient expression assay was established in which 57 ug of circular pPF4GH was transfected by electroporation into cells and the amount of HGH produced was measured in the media after 88 hr in culture.
• the assay conditions allow measurement of plasmid expression to be carried out within a linear range of response.
• Fibroblasts were transfected by the DEAE-dextran method (McCutchan, J.H. and J.S. Pagano, J. Natl. Cancer Inst. £1:351-356 (1968)). To this end, 35 mm culture dishes were inoculated with 1-2x10 cells. After 24 hr, the cells were rinsed with serum-free DMEM and the
• DEAE-dextran mixture was added [400 ug/ml of DEAE dextran (molecular weight 500,000), 8 ug/ml of chloroquine, 25 ug/ml of circular plasmid DNA and 8 ug/ml of sonicated herring sperm DNA in 1 ml of serum-free DMEM] . After incubation at 37°C in 5% co_ for 1 hr, the DEAE-dextran mixture was removed and 1 ml of 10% dimethyl sulfoxide (DMSO) in HEPES-buffered saline was added (Parker, B.A. and G.R. Stark, J. Virol. 31:360-369 (1979)).
• DMSO dimethyl sulfoxide
• the cells were incubated at room temperature for 3 min, washed with DMEM three times, and cultured in 3 ml of DMEM containing 10% fetal bovine serum, 100 U/ml of penicillin and 100 ug/ml of streptomycin at 37°C in 5% CO- for 72 hrs.
• the non-adhering rat bone marrow cells were removed from wells, ce ' ntri- fuged at 380 xg for 5 min, washed with 2 ml CATCH (Kuter, D.J. et al. , Blood 74:1952-1962 (1989)), subjected either to botrocetin treatment or resuspended in 0.3 ml of H.O, and lysed by freezing and thawing twice.
• the adhering cells were scraped off the culture dishes in the presence of 1 ml of ice-cold CATCH, harvested as outlined above, washed with 2 ml ice-cold CATCH, and lysed as described above.
• HGH human growth hormone
• the levels of HGH expressed by the transfected cells were measured in the media and cell lysate by radioimmunoassay (Selden, R.F. et al., Mol. Cell. Biol. (5:3173-3179 (1986)).
• the standard curve used for HGH was linear from 0.02-0.5 ng/ml and from 0.5-50 ng/ml with a break point at 0.5 ng/ml.
• Hirt Assay The average amount of plasmid DNA transfected into the various cell types was determined by Hirt assay (Hirt, B., J. Mol. Biol. 26:365-369 (1967)) of pooled lysed adhering and non-adhering cells.
• the cells were lysed by incubation for 2 hr at 4°C with 0.8 ml/plate of 0.6% SDS, 0.01 M EDTA, pH 7.5, 3 mg/ml of calf DNA employed as a carrier, and 410 pg/ l of TM control plasmid used to standardize the variable recovery of transfected plasmid DNA. NaCl was then added to a final concentration of 1.0 M, and the resultant mixtures were maintained overnight at 4°C.
• the lysates were centrifuged at 7000 xg for 20 min at 4°C, 0.7 ml of the supernatants were treated with DNAse-free RNAse (50 ug/ml) , and DNA was extracted with phenol-chloroform followed by precipitation with ethanol as well as a 70% ethanol wash.
• the DNA was then digested with EcoRI and quantitated by Southern blot analysis using the 1.85 kB BamHI/Sphl fragment of the HGH gene as a probe (Selden, R.F. et al. , Mol. Cell. Bio. :3173-3179 (1986)) with a Betascope 603 blot analyzer (Betagen) . The results obtained from each plate were normalized to 100% recovery of the TM control plasmid.
• the filtrated (megakaryocyte-depleted) cells were collected by centrifugation at 380 xg for 5 min and then resuspended in H_0 for HGH determinations or in SDS buffer for Hirt assays. The number of filtrated cells was greater than 98% of the total number of cells counted prior to filtration.
• the supernatants of the pelleted megakaryocyte-depleted cells were also analyzed for HGH and the amounts observed were added to those found in the cell lysates.
• the transient expression of the various plasmids with rat bone marrow megakaryocytes was deduced by comparing results of HGH and Hirt assays for whole cell populations with those for the megakaryocyte- depleted cell populations. We attempted to recover megakaryocytes retained by the 17 um nylon mesh in order to carry out assays directly on this cell type. However, the recovery of HGH following sonication was poor while detergents interfered with the HGH assay.
• RNAs from transfected or non-transfected cells were prepared by the CsCl cushion method (Chirgwin, J.M. et al ⁇ . , Biochemistry
• Si Nuclease Protection experiments were conducted to establish the 5' ends of GH mRNAs generated during transient expression assays with PF4GH and its various 5' deletants. The single stranded probe utilized for the above studies was prepared by subcloning a 1350 bp Hindlll-Sacl fragment of pPF4GH into M13mpl9, and then isolating viral DNA.
• a 20 nucleotide primer was synthesized complementary to nucleotides 24 to 53 of human GH mRNA.
• the primer was annealed to the single stranded M13 DNA, extended by addition of DNTPs and T7 DNA polymerase, and digested with Bgll (site at -117 in the PF4 gene) .
• Bgll site at -117 in the PF4 gene
• the resultant product was electrophoresed on a 4% polyacrylamide-8 M urea gel, the 206 bp single stranded probe was located, excised and recovered by elution.
• the studies to map the 5" end of HGHmRNA were carried out as described in (Emorine, L.J. et al. , Proc. Natl. Acad. Sci. USA 84:6995-6999 (1987)).
• HEL human erythroleukemia cell
• pPF4GH chimeric gene
• the HEL cells were transfected by electroporation with pPF4GH or plasmids containing varying lengths of the 5" upstream region of the PF4 gene, and transient expression assays for secreted HGH were carried out as outlined above.
• the results delineate several major potential regulatory domains which significantly modify transcriptional activity of neighboring regions (Table 1) .
• the plasmid number indicates the 5' end of each plasmid deletion.
• the levels of HGH secreted represent an average of 2 experiments.
• the sensitivity of the HGH assay is in the range of >0.05 ng/plate.
• the amount of plasmid detected by HIRT assay in the cells transfected with the pPF4GH was arbitrarily defined as 1 unit and the levels of the different plasmid deletions detected by HIRT assay were expressed as a function of the level obtained with pPF4GH.
• the amounts of secreted HGH generated by the different constructs were then divided by the relative levels of intracellular plasmid
• the elimination of upstream sequences beyond -50 reduces secreted HGH from 40 ng/plate to undetectable levels, indicating that critical regulatory domains exist in the 5' region of the gene as previously surmised from the transfection of the entire PF4 gene.
• RNA obtained from these various cells was found to protect a single stranded labeled DNA fragment of 89 bases which corresponds to the transcriptional start site of the PF4 gene.
• the levels of protected fragment are in excellent accord with measurements of secreted HGH carried out at the same time with the same cells.
• PF4 Promoter in Rat Bone Marrow Megakaryocytes
• the short term culture system is composed of nonadhering progenitor and mature cells of the erythroid, lymphoid, myeloid and megakary ⁇ cytic lineage as well as adhering phagocytes, epithelial cells, and adipocytic cells (Ebbe, S. and F. Stohlman, Jr., Blood 26:20-35 (1965); Martin, D.I.K. et al., Nature 334:444-447 (1990)).
• the megakaryocytes comprise about 1% of nonadhering cells with a polyploid distribution similar to that of normal iji vivo bone marrow.
• the transfected non-adhering cells were placed on glass slides, treated with 1251 labeled anti-HGH antibody, subjected to autoradiography, and then stained for acetylcholmesterase, a specific marker of rodent megakaryocytes (Kuter, D.J. et aL. , Blood 74:1952-1962
• Rat bone marrow cells were transfected, cultured and depleted of megakaryocytes by botrocetin as outlined in Materials and Methods. Cells from two plates were pooled for determining the expression of each plasmid. The results provided are of a representative experiment.
• HGH HGH
• PPF4GH PPF4GH
• the trace levels of HGH associated with adhering cells may be due to endocytosis of hormone generated by the nonadhering cells, as suggested by the observation that non-transfected adhering cells internalized small amounts of HGH added to the incubation media (Table 2).
• the HGH present in the nonadhering cells was shown by differ ⁇ ential agglutination of megakaryocytes to be located within this cell type.
• Botrocetin is a snake venom protein (Howard, M.A. et a_l. , Br. J. Haematol.
• megakaryocyte-specific gene expression can be determined by comparing the amounts of HGH in nonadhering bone marrow cells to that in the same cell population following addition of botrocetin and separation of agglutinated cells by filtration through 17 ⁇ m nylon mesh.
• the regions of the PF4 gene which are responsible for regulating lineage-specific expression were initially defined by carrying out 5' deletions of the promoter in pPF4GH.
• Transient expression of pPF4GH in bone marrow cells is substantial whereas removal of the upstream sequences (deletions to -50 and -12) reduces secreted HGH to undetectable levels.
• the transfection of rat bone marrow cells with plasmids containing varying lengths of the 5" upstream region delineates potential regulatory domains whose removal alters transcriptional activity by 5-30 fold.
• These regions include positive-acting domains at -372 to -355, -272 to -257, -151 to -125, -97 to -83, and negative-acting domains at -332 to -291, -184 to -152 (thymidine cluster) and -124 to -98.
• the above changes in expression are not caused by the positioning of vector sequences close to PF4 domains since a similar overall pattern of HGH secretion, but with a 10 fold reduced amplitude, is noted with 5' deleted linearized constructs containing only PF4 and HGH sequences.
• the botrocetin technique was used to ascertain whether the various 5' deletions of the PF4 promoter are expressed solely in megakaryocytes.
• the HGH concen- trations in the megakaryocyte-depleted fraction of the sa e bone marrow cells are rather constant averaging about 10% of that observed with the whole cell population until the deletion reaches position -97, when a small increment of about 6% is observed.
• These data indicate that removal of sequences upstream of -97 allows low level HGH expression in non-megakaryocytes.
• These results also reveal that changes in transcriptional activity of the 5' upstream region deleted to -151 and probably -97 are due to altered expressed in megakaryo- cytes rather than aberrant expression in other bone marrow cells.
• This domain also decreases expression of HGH in bone marrow cells depleted of megakaryocytes and in fibro ⁇ blasts by about 3-4 fold. Therefore, this element alters overall levels of HGH in megakaryocytes relative to other bone marrow cells by about 16 fold.
• the region from -448 to -112 functions in either orientation or when posit ⁇ ioned 1234 bp upstream of the heterologous promoter. Similar sets of experiments have been conducted with the CMV promoter linked to the coding region of the ⁇ -gal- actosidase gene with virtually identical results.
• the interactions between the core promoter from -97 to the transcriptional start site, the enhancer/silencer domain from -448 to -112, and the region from -1104 to -449 were evaluated by mutations as well as internal deletions/replacements with pPF4GH.
• the effects of these alterations on megakaryocyte expression were ascertained by comparing the level of HGH generated by a given plasmid in the megakaryocyte population to that produced by pPF4GH.
• the effects of these changes on lineage- specific expression were determined by comparing the percentage of HGH generated by a given plasmid in the non-megakaryocytic population to that in cells trans ⁇ fected with pSVTKGH.
• the core promoter was examined by deletions/ mutations in order to identify the element(s) responsible for the relatively restricted expression of plasmid -97 in bone marrow cells. Deletion of the positive-acting domain from -97 to -83 in pPF4GH reduces transcriptional activity in megakaryocytes by 3 fold but has no effect on lineage specificity. GATA sequences have been previously described as binding sites for transacting factors involved in gene regulation of hematopoeitic cells (Martin, D.I.K. et al. , Nature 334:444-447 (1990)).
• Mutation of the GATA sequence at -31 to -28 in pPF4GH to AATA or to TATA does not significantly affect the trans ⁇ cription of pPF4GH in megakaryocytes but causes a partial loss of lineage specificity and low level expression in fibroblasts. Mutation of the GATA sequence in pPF4GH deleted to -97 leads to a complete loss of lineage specificity and a significant decrease of transcription in megakaryocytes. It is also of interest to note that the same plasmid exhibits an enhanced level of expression when transfected into fibroblasts.
• the enhancer/silencer domain was analyzed to confirm elements involved in tissue-specific expression.
• the deletion of the entire enhancer/silencer domain from -448 to -112 leads to a three fold reduced expression in megakaryocytes as well as a significant decrease in lineage-specificity and to a moderate expression in fibroblasts. This should be contrasted with the rather minor effect on lineage-specificity observed upon 5' deletion of this domain.
• the region from -448 to -112 leads to a three fold reduced expression in megakaryocytes as well as a significant decrease in lineage-specificity and to a moderate expression in fibroblasts. This should be contrasted with the rather minor effect on lineage-specificity observed upon 5' deletion of this domain.
• the region from -448 to -112 leads to a three fold reduced expression in megakaryocytes as well as a significant decrease in lineage-specificity and to a moderate expression in fibroblasts. This should be contrasted with the rather minor effect on lineage-specific
• -1104 to -449 contains a non-tissue-specific regulatory sequence which might play a dominant role in gene trans ⁇ cription after removal of the enhancer domain.
• the examination of enhancer/silencer subdomains placed upstream of a heterologous promoter suggested that P3 plays an important role in lineage-specific expression. Therefore, we tested whether the effects of grossly removing the entire enhancer/silencer domain from pPF4GH are duplicated by eliminating P3. Deletion of P3 reduces expression in megakaryocytes by about two fold, but also induces transcription in other bone marrow cells, albeit, to a lesser extent than observed with gross removal of the enhancer/silencer domain.
• deletion of PI, P2 and P3 as compared to removal of P3 is only moderately more effective in altering the function of the enhancer/ silencer domain.
• deletions of PI, P2 or PI and P2 have only a minimal impact on lineage-specific expression.
• removal of the negative-acting subdomain Nl or its replacement with (AT). enhances expression by about two fold in megakaryocytes without permitting transcription in other bone marrow cells.
• datin which binds to poly dT:poly dA but not to poly dAT:poly dAT has been isolated from yeast (Winter, E. and A. Warshavsky, The Embo. J. 8:1867-1877 (1990)). It is possible that a protein homologous to detin may function as a suppressor of PF4 gene expression.
• the plasmid pPF41acZ was constructed by inserting a 1.1 kb rat PF4 NdelBan II genomic fragment which includes 1104 bases of 5' upstream sequence as well as the cap site to + 20 into a PUC19 based plasmid designated as pSDKlacZpA (a generous gift from Dr. Janet Rossant, Mount Sinai Research Institute, Toronto, Canada) .
• This latter plasmid contains the 3.34 kb prokaryotic ⁇ -galactosidase gene without its upstream regulatory region flanked by a unique Hind III site at the 5' end and a unique Bam HI site at the 3' end.
• PF41acZ was accomplished by ligating the rat genomic fragment to Hind III linearized pSDKlacZpA with synthetic linkers TCGGTCGA (Ban II to Hindlll) and AGCTGGGCCCCA (Ndel to Hindlll)
• CCCGGGGTAT respectively, which creates a unique Apa I site at the 5' end of the megakaryocyte promoter.
• the PF4 promoter / ⁇ - galactosidase gene of 4.4 kb can be removed from pPF4lacZ as a unit free of vector sequences by cutting with Apa I and Kpn I.
• Example 3 Production of Transgenic Mice and Assess ⁇ ment of ff-Galactosidase Activity
• the 4.4 kb Apa I-Kpn I fragment of pPF41acZ was isolated by agarose gel electrophoresis, purified by C-TAB (International Biotechnologies, Inc.), diluted to 2 ug/ml in 10 mM Tris buffer, pH 7.5 containing 0.25 mM EDTA, and injected into the pronuclei of fertilized eggs from superovulated female mice (FVB/ NTacfBR, Taconic) as previously described.
• Hogan, B. et aL. Manipulating the Mouse Embryo, A Laboratory Manual, Cold Spring Harbor Laboratory (1986) .
• Injected embryos were reimplanted into pseudopregnant outbred females (CD-I, Charles ' River) , and offspring were screened for transgene integration by Southern blot hybridization of tail DNA with a 32P-labelled 3.34 kb prokaryotic B-galactosidase
• mice Two founder mice (founder 10 and founder 12) were identified out of 12 mice produced. Both founders were mated to CD-I females to generate Fl transgenic heterozygous and homozygous mice. Founder 10 transmitted the transgene to its progeny in a Mendelian fashion. Founder 12 was presumed to be mosaic as only 1 out of 22 offspring was transgenic but subsequent inheritance was as predicted for a normal autoso al locus. Southern analyses of founders as well as Fl progeny and F2 offspring utilizing EcoRI showed a single band of 4.4 kb. Heterozygous and homozygous F2 mice were easily identified by gene dosage.
• tissue distribution of -galactosidase was ascertained by a combination of in situ staining of isolated blood cells as well as tissues, flow cytometric analyses of bone marrow cells, and enzymatic assay of blood cells as well as tissue homogenates.
• mice as well as their normal litter mates were anesthetized with ether prior to sacrifice.
• the organs obtained included adrenal gland, brain, bone marrow, heart, intestine, kidney, liver, lung, skeletal muscle, spleen, and thymus.
• Tissue samples were immed ⁇ iately fixed for 1 hr at 4°C with 2% (w/v) paraformalde- hyde in 0.1 M PIPES buffer, pH 6.9, supplemented with 2mM MgCl 2 and 1.25 mM EGTA, incubated for 3 hr at 4°C with PBS supplemented with 2mM gCl 2 and 30% sucrose, embedded in OCT (Miles, Inc.) and frozen on dry ice.
• OCT OCT
• Blood samples were obtained from transgenic mice and their normal litter mates by cardiac puncture. Peripheral blood cells were isolated by centrifugation for 8 min at 800xg, platelets were harvested by centri- fugation for 15 min at 3l60xg, and femoral bone marrow cells were collected as previously described. Burstein, S.A. et al., Blood 5_4:169-179 (1979). Blood and bone marrow cells were streaked on glass slides and stained with Wright's stain.
• Suspended blood and bone marrow cells were also fixed for 15 min with 0.5% glutaraldehyde in PBS containing 2 mM MgCl_, and stained at 37°C for varying periods of time with modified X-Gal solution [7mMK 3 Fe(CN) 6 ; 7 mM K 4 FE(CN) 6 .3H 2 0; 2 mM MgCl 2 ; o.o2%
• Bone marrow cells that exhibit -galactosidase activity were isolated by fluorescence activated cell sorter (FACS) , and the cell populations obtained were identified with respect to cell type and DNA content.
• FACS fluorescence activated cell sorter
• the ⁇ -galactosidase positive cell population was identified by employing as negative controls cells from the same transgenic animal which had not been loaded with the FDG substrate, as well as cells from normal litter mates which had been loaded with the FDG substrate.
• the cell population with a DNA content of 2N was identified by assuming that the majority of ungated cells possessed the above amount of DNA.
• Cell populations with a DNA content of 4N through 32N were identified by the fluorescence intensity of the bound Hoechst dye.
• the cell populations of differing ploidy which exhibited ⁇ -galactosidase activity were sorted, and then stained for the lineage specific megakaryocyte marker, acetyl- cholinesterase, as previously described. Burstein, S. A. et al., J. Cell Physiol. 109:333-341 (1981).
• the various organs, bone marrow cells, and platelets were quantitatively assayed for ⁇ - galactosidase activity.
• the cells and organs were solu- bilized by adding 0.1 to 0.4 gm of tissue to 2-3 ml of lmM EDTA, 5 mM dithiothreitol, and 7% glycerol in 20 mM Tris buffer, pH 7.4 and then homogenizing the mixtures on ice with a Polytron homogenizer (PCU-2; Brinkmann Instru ⁇ ments). The homogenates were centrifuged at 4°C for 20 min at I10,000xg, supernatants were collected, and then assayed for protein content by the method of Lowry et al.
• bone marrow cells or platelets were lysed with PM solution [60 mM Na 2.HPO4,; 40 mM NaH2_PO4 token; 10 mM KCL; 1 mM MgCl 2 ; 50 mM B-mercaptoethanol] supplemented with 0.02% NP-40.
• the lysates were centrifuged at 4°C for 15 min in a microcentrifuge, the supernatants were collected, and then assayed for protein content as outlined above.
• the amounts of enzymatic activity present in the above samples were determined by adding 0.01-0.05 ml of the supernatant (30 ug of solubilized protein) to 0.8 ml of PM solution and 0.2 ml of 0-nitro- phenyl galactopyranoside ( gm/ml) (ONPG) , and then monitoring the absorbance at 420 nm after varying lengths of time at 37°C. For each time point, the value obtained for a given nontransgenic tissue homogenate was sub ⁇ tracted from the value obtained for the same transgenic tissue extract. The concentrations of j9-galactosidase in megakaryocytes were calculated by multiplying whole bone marrow values by 120 fold.
• This correction factor is derived from the relative frequency of megakaryocytes within the bone marow, and the relative size of this polyploid cell as compared to other cell types (see below) .
• Prior experiments demonstrated that the homogenization procedure has minimal effect on ⁇ -galactosidase activity since the calculated recovery of purified enzyme added during the initial solubilization is greater than 90%.
• RNA per lane were then electrophoresed on 1% agarose/formaldehyde gels, blotted onto GENENTRAN nylon membranes (Plasco Inc. , MA) , and hybridized with 32P labelled probe which is specific for rodent PF4 mRNA. After washing, the membranes were examined by Betascope (Betagen, Co.,
• mice were investigated for expression of 3-galactosidase in peripheral blood cells, bone marrow progenitor cells, splenic cells, and thymic cells. The results described below were obtained with line 10 transgenic mice but identical data were generated with line 12 transgenic mice. Blood smears were prepared from transgenic mice as well as normal litter mates, and then examined by in situ staining for ⁇ -galactosidase utilizing X-Gall as substrate as outlined in Methods.
• Figure 2A shows that small, anucleated platelets of transgenic animals but not their normal litter mates stain for ⁇ -galactosidase whereas red cells and white cells from both types of mice do not contain the prokaryotic enzyme.
• blood from the two types of mice was processed to obtain fractions containing either platelets or red cells and nucleated white cells.
• Figures 2B and 2C reveal that platelets from transgenic mice stain intensely for 0-galactosidase whereas those from normal itter mates do not possess the prokaryotic enzyme. Examination of the red cell/nucleated white cell fractions from both types of mice showed no staining for 0-galactosidase.
• bone marrow cells were prepared from both types of mice as described above and then examined by in situ staining for ⁇ -galactosidase.
• Figures 2D and 2E indicate that 0.05% to 0.10% of the nucleated bone marrow cells of transgenic mice but not their normal litter mates stain positive for ⁇ -galactosi- dase and exhibit diameters that range from about 20 microns to about 70 microns (normal hemopoietic cell diameters are 10 to 15 microns) .
• Th frequency and size of these ⁇ -galactosidase positive cells are typical of bone marrow megakaryocytes.
• transgenic bone marrow cells were stained for 0-galactosidase with the fluorescent substrate fluorescein-di-galactoside as well as for DNA content with Hoechst dye, and then subjected to flow cytometry as outlined in Methods.
• the transgenic bone marrow cells contained prokaryotic ⁇ -galactosidase with 26.9% of the total enzymatic activity in the 2N peak, 16.8% of the total enzymatic activity in the 4N peak, 10.1% of the total enzymatic acitivity in the 8N peak, 43.8% of the total enzymatic activity in the 16N peak and 2.4% of the total enzymatic activity in the 32N peak.
• the ⁇ -galactosidase positive cells were sorted and then stained for the rodent megakaryocyte specific enzyme, acetylcholmesterase. Burstein, A. S. et al., Blood 5_4:169-179 (1979). All cells including those obtained from the 2N peak possessed this lineage specific marker which confirms that bone marrown megakaryocytes selec- tively express PF41acZ.
• adrenal gland, brain, heart, intestine, kidney, liver, lung, and skeletal muscle were isolated from transgenic mice as well as from normal litter mates.
• the tissues were processed and examined by in situ staining for ⁇ -galactosidase as outlined above.
• the organs tested showed no staining for 0-galactosidase, except for the consistent intense reaction of the transgenic adrenal cortex and the occasional weak reaction of the transgenic and nontransgenic endocardium.
• Figure 3 shows the ⁇ -galactosidase staining of the transgenic adrenal cortex; no such reaction was observed in the same organ from a normal litter mate.
• PF41acZ transgene expression in the various organs were quantitated by kinetic (initial rate) assay of tissue homogenates for ⁇ -galacto ⁇ sidase activity per given amount of protein utilizing o-nitrophenyl galactopyranoside as substrate as outlined above. Based upon two separate experiments with line 10 mice, it was determined that megakaryocytes contain 6.00 units of -galactosidase activity/30 ug of protein and that adrenal glands contain 0.11 units of ⁇ -galacto- sidase activity/30 ug of protein.
• the brain, heart, intestine, kidney, liver, lung, skeletal muscle, spleen, and thymus possess no detectible amounts of prokaryotic enzyme.
• transgene expression in megakaryocytes is about 50 fold greater than in adrenal gland, and at least 200 fold above other organs.
• the levels of ⁇ -galacto ⁇ sidase in the adrenal gland confirm the unexpected expression of the transgene in the endocrine organ.
• the quantitative results outlined above are in excellent agreement with the more qualitative observations made with in situ staining. For example, note the intense staining of megakaryocytes, the readily apparent but greatly reduced in situ staining of adrenal gland ( Figure 3A) , and the complete absence of in situ staining for other organs.
• PF4 gene might be transcribed at low levels within the adrenal gland.
• Northern analyses were carried out on mouse or rat adrenal gland. They revealed a faint band of the same size as PF4 mRNA. Examination of other organs such as kidney also showed a barely detectible band in the same region.
• Northern analyses of varying concentraions of platelets suggested that the trapping of small numbers of these blood cells within the circulatory system of the various organs could explain the above observations.
• the use of other megakaryocyte specific DNA probes, such as GpIIb, to correct for potential platelet contamination proved fruitless because of the relatively low levels of expression of these genes vis a vis PF4.
• the PF4 gene is actively transcribed within the adrenal gland.
• the megakaryocyte message is produced at low levels similar to that contributed by platelets trapped within the circulatory system of this endocrine organ.
• the adrenal gland may express transacting factors similar to those which control the megakaryocyte promoter.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Molecular Biology (AREA)
• Zoology (AREA)
• Biophysics (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Biochemistry (AREA)
• Wood Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biomedical Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Endocrinology (AREA)
• General Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Gastroenterology & Hepatology (AREA)
• Environmental Sciences (AREA)
• Biodiversity & Conservation Biology (AREA)
• Oncology (AREA)
• Animal Husbandry (AREA)
• Plant Pathology (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Toxicology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Public Health (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=24366639

Family Applications (1)

Country Status (2)

Families Citing this family (4)

• 1991
  • 1991-10-01 EP EP19910919045 patent/EP0561797A1/de not_active Withdrawn
  • 1991-10-01 WO PCT/US1991/007233 patent/WO1992006190A1/en not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events